^
Association details:
Evidence:
Evidence Level:
Sensitive: C4 – Case Studies
Title:

Therapeutic Potential of Afatinib in NRG1 Fusion-Driven Solid Tumors: A Case Series

Published date:
09/23/2020
Excerpt:
The patient with colorectal cancer harbored a novel POMK‐NRG1 fusion and a KRAS mutation….In May 2018, the patient underwent lung metastasectomies. Caris® (Irving, TX) NGS profiling identified a novel POMK‐NRG1 fusion in both lung and liver metastases….Afatinib 30 mg/day was initiated in September 2018, with a reduction in CEA from 190 μg/mL to 163 μg/mL observed in October 2018 (Fig. ​(Fig.2).2). In November 2018, a CT scan showed SD, and the CEA was 292 μg/mL.
DOI:
10.1634/theoncologist.2020-0379